Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
about
Zoledronic acid: an unending tale for an antiresorptive agent.Docetaxel-based combination therapy for castration-resistant prostate cancer.Life-threatening dermatologic adverse events in oncologyPhase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.
P2860
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Weekly docetaxel, zoledronic a ...... actory prostate cancer (HRPC).
@ast
Weekly docetaxel, zoledronic a ...... actory prostate cancer (HRPC).
@en
type
label
Weekly docetaxel, zoledronic a ...... actory prostate cancer (HRPC).
@ast
Weekly docetaxel, zoledronic a ...... actory prostate cancer (HRPC).
@en
prefLabel
Weekly docetaxel, zoledronic a ...... actory prostate cancer (HRPC).
@ast
Weekly docetaxel, zoledronic a ...... actory prostate cancer (HRPC).
@en
P2093
P1476
Weekly docetaxel, zoledronic a ...... actory prostate cancer (HRPC).
@en
P2093
Cancer Research Group
Fady L Nasr
Fady S Farhat
Fariha C Younes
Georges Y Chahine
Joseph G Kattan
Marwan G Ghosn
Nadine J Yazbeck
Walid T Moukadem
P2888
P356
10.1007/S10637-007-9074-3
P577
2007-09-06T00:00:00Z
P6179
1046462340